VVP
IMGN

Venture Visionary Partners’s Immunogen Inc IMGN Stock Holding History

Venture Visionary Partners’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-130
Closed -$585 – 1635
2022
Q2 		$585 Buy
+130
New +$565 ﹤0.01% 1637

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Venture Visionary Partners's IMGN Position: Q3 2022 in Review

Venture Visionary Partners sold out of Immunogen Inc (IMGN) in Q3 2022, closing a stake of 130 shares — an estimated $585 sold.

Venture Visionary Partners first reported a position in IMGN in Q2 2022 and held it in 1 quarter. The position peaked at $585 in Q2 2022. 222 funds tracked by Wall St. Rank hold IMGN as of Q3 2022.

  • Venture Visionary Partners reported no remaining Immunogen Inc position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 130 Immunogen Inc shares in Q3 2022, an estimated $585.
  • Venture Visionary Partners first reported a position in Immunogen Inc in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Immunogen Inc position peaked at $585 in Q2 2022.
  • 222 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.